U.S. markets closed

Silo Pharma, Inc. (SILO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1667+0.0067 (+4.19%)
At close: 03:15PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1600
BidN/A x N/A
AskN/A x N/A
Day's Range0.1556 - 0.1680
52 Week Range0.1200 - 0.4950
Avg. Volume142,434
Market Cap16.449M
Beta (5Y Monthly)-1.78
PE Ratio (TTM)5.38
EPS (TTM)0.0310
Earnings DateNov 11, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for SILO

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    Analyst Report: Constellation Brands, Inc.Constellation Brands is the largest multi-category alcohol supplier in the U.S. The business is anchored by a portfolio of Mexican beer trademarks, including Corona and Modelo, for which it acquired exclusive and perpetual U.S. ownership from AB InBev. The latter had to divest these rights due to antitrust mandates as it consummated its 2013 acquisition of dominant Mexican brewer, Grupo Modelo. Constellation’s wine/spirits business is in transition, and it has divested several lower-margin assets, including myriad wine brands and its Ballast Point craft beer brand. The firm imports most products after manufacturing them abroad, going to market through independent wholesalers. It owns 38.6% of Canopy Growth, a leading provider of medicinal and recreational cannabis products.
    Fair Value
    Economic Moat
    8 days agoMorningstar
View more
  • GlobeNewswire

    Silo Pharma, Inc. Engages Donohoe Advisory to Assist with its Efforts to Obtain a Listing on a National Stock Exchange

    Englewood Cliffs NJ, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, announced the engagement of Donohoe Advisory Associates LLC ("Donohoe") for consulting and advisory services in connection with the potential up-listing of Silo’s common shares on the NASDAQ Stock Market. Silo Pharma hopes to gain additional exposure and access to a wider base of retail and institutional investor

  • GlobeNewswire

    Silo Pharma Announces Grant of U.S. Patent For its Novel CNS Homing Peptide

    U.S. Patent and Trademark Office issued US Patent No. 11,174,287 investigation, detection, treatment or prevention of neuroinflammationEnglewood Cliffs NJ, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic announced the issuance of a patent relating to its University Maryland Baltimore licensed homing peptide. The novel homing peptide can be used for enhanced targeting of therapeutic

  • GlobeNewswire

    Silo Pharma and Strategic Partner Zylo Therapeutics Begin Development Process for Novel Ketamine Loaded Z-Pods

    Englewood Cliffs NJ, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that their joint venture partner Zylo Therapeutics received its first ketamine shipment and initiated loading ketamine into their Z-Pod® transdermal technology. Eric Weisblum, CEO of Silo Pharma stated “The commencement of Novel Ketamine loaded Z-Pods is a pivotal advancement for administering Ket